GoldBamboo.com - Knowledge is strong medicine
  

Threshold Pharmaceuticals Announces That A Phase 3 Clinical Trial Of Glufosfamide For Treatment Of Pancreatic Cancer Did Not Meet Its Primary Endpoint - News


  Not Signed In - Sign In / Register




General Topics A-Z

Threshold Pharmaceuticals Announces That A Phase 3 Clinical Trial Of Glufosfamide For Treatment Of Pancreatic Cancer Did Not Meet Its Primary Endpoint

Tue, 27 Feb 2007 08:00 AM EST

... Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), today announced that a Phase 3 trial of glufosfamide did not show a statistically significant improvement in overall survival compared to best supportive care (BSC) in patients with metastatic pancreatic cancer who had relapsed after gemcitabine chemotherapy. [click link for full article] ...

Related Topics

Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $50 a year, a savings of 50% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

GoldBambooTM

Your Integrative Health and Wellness Resource

July 23, 2008


Page Updated: June 12, 2007
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Insurance Quotes | Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Google Co-op | Health Forums

Copyright © 2004-2008 - Gold Bamboo LLC
All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.